Silexion Therapeutics (SLXN) CFO receives 49,726-share equity grant

Rhea-AI Filing Summary

Silexion Therapeutics Corp reported that CFO and Secretary Hadar Mirit Horenshtein acquired 49,726 Ordinary Shares on account of a fully vested restricted share unit grant. The RSUs were immediately settled into ordinary shares as compensation for service as an officer, approved by the board of directors.

Following this grant, Horenshtein directly owns 50,146 Ordinary Shares of Silexion Therapeutics Corp.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horenshtein Hadar Mirit

(Last) (First) (Middle)

6 SHOSHANA DAMARI STREET

(Street)

HERZLIYA L3 4606450

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	02/20/2026		A(2)		49,726	A	$0	50,146	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively.

2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's service as an officer of the Issuer. The grant was approved by the Issuer's board of directors.

	/s/ Mirit Horenshtein Hadar	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Silexion Therapeutics (SLXN) report for its CFO?

Silexion Therapeutics reported that CFO and Secretary Hadar Mirit Horenshtein received a grant of 49,726 fully vested restricted share units. These RSUs were immediately settled into ordinary shares as compensation for service as an officer, with the grant approved by the company’s board of directors.

How many Silexion Therapeutics (SLXN) shares did the CFO acquire in this Form 4?

The CFO acquired 49,726 Ordinary Shares of Silexion Therapeutics through a grant of fully vested restricted share units. These RSUs were immediately converted into underlying ordinary shares, reflecting equity compensation rather than an open-market purchase of the company’s stock.

What is the CFO’s total Silexion Therapeutics (SLXN) shareholding after this grant?

After the reported transaction, CFO and Secretary Hadar Mirit Horenshtein directly owns a total of 50,146 Ordinary Shares of Silexion Therapeutics. This total incorporates the 49,726 shares received from the fully vested restricted share unit grant described in the Form 4 filing.

Was the Silexion Therapeutics (SLXN) CFO’s equity grant an approved board action?

Yes. The Form 4 states that the grant of fully vested restricted share units to the CFO was approved by Silexion Therapeutics’ board of directors. The RSUs were then immediately settled into ordinary shares as part of the officer’s compensation package.

Did the Silexion Therapeutics (SLXN) CFO pay cash for the 49,726 acquired shares?

No cash payment was made for these shares. The Form 4 shows a transaction price per share of $0.0000, indicating the 49,726 Ordinary Shares were issued through a grant of fully vested restricted share units as compensation, not through a market purchase.

How do reverse share splits affect the share numbers in the SLXN CFO Form 4?

The Form 4 notes that reported ordinary share numbers reflect adjustments for a 1-for-9 and a 1-for-15 reverse share split. These reverse splits were effected on November 29, 2024 and July 29, 2025, aligning current holdings with the post-split capital structure.